← Back to Search

Anti-metabolites

Capecitabine-tesetaxel for Stomach Cancer (TESEGAST Trial)

Phase 2
Waitlist Available
Research Sponsored by Genta Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 30 days after the last dose of study medication
Awards & highlights

TESEGAST Trial Summary

This study is being performed to evaluate the efficacy and safety of capecitabine in combination with tesetaxel versus capecitabine in combination with placebo as second-line treatment for patients with gastric cancer.

Eligible Conditions
  • Stomach Cancer

TESEGAST Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 30 days after the last dose of study medication
This trial's timeline: 3 weeks for screening, Varies for treatment, and through 30 days after the last dose of study medication for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall survival
Secondary outcome measures
Disease control rate
Incidence of adverse events
Progression-free survival
+1 more

TESEGAST Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Capecitabine-tesetaxelExperimental Treatment2 Interventions
21-day cycle; tesetaxel 27 mg/m2 orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
Group II: Capecitabine-placeboActive Control2 Interventions
21-day cycle; placebo orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tesetaxel
Not yet FDA approved
Capecitabine
FDA approved

Find a Location

Who is running the clinical trial?

Genta IncorporatedLead Sponsor
30 Previous Clinical Trials
1,090 Total Patients Enrolled
Jaffer Ajani, MDStudy ChairThe University of Texas MD Anderson Cancer Center
8 Previous Clinical Trials
1,335 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
2012. "Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01573468.
All > Debbies Dream > Gastric Cancer
~44 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top